Preparation of recombinant vaccines

作者: Eric Soler , Louis-Marie Houdebine

DOI: 10.1016/S1387-2656(07)13004-0

关键词:

摘要: Vaccination is one of the most efficient ways to eradicate some infectious diseases in humans and animals. The material traditionally used as vaccines attenuated or inactivated pathogens. This approach sometimes limited by fact that for vaccination not efficient, available, generating deleterious side effects. A possible theoretical alternative use recombinant proteins from implies having capacity vaccinate have been identified they can be produced sufficient quantity at a low cost. Genetically modified organisms harboring pathogen genes fulfil these conditions. Microorganisms, animal cells well transgenic plants animals source vaccines. Each systems are all getting improved has advantages limits. Adjuvants must generally added enhance their vaccinating capacity. purified avoid any immunization against contaminants. efficiency vaccine poorly predictable. Multiple various modes administration therefore empirically evaluated on case-by-case basis. structure proteins, composition adjuvants mode strong fully predictable impact immune response protection level Recombinant theoretically also carriers epitopes other increasing knowledge genomes availability prepare large amounts greatly facilitate potential present review critical analysis state art this field.

参考文章(116)
Tim Edmunds, Scott M. Van Patten, Julie Pollock, Eric Hanson, Richard Bernasconi, Elizabeth Higgins, Partha Manavalan, Carol Ziomek, Harry Meade, John M. McPherson, Edward S. Cole, Transgenically Produced Human Antithrombin: Structural and Functional Comparison to Human Plasma–Derived Antithrombin Blood. ,vol. 91, pp. 4561- 4571 ,(1998) , 10.1182/BLOOD.V91.12.4561
Pia Villa, Pietro Ghezzi, Animal Models of Endotoxic Shock Methods in molecular medicine. ,vol. 98, pp. 199- 206 ,(2004) , 10.1385/1-59259-771-8:199
G. M. Glenn, R. T. Kenney, Mass vaccination: solutions in the skin. Current Topics in Microbiology and Immunology. ,vol. 304, pp. 247- 268 ,(2006) , 10.1007/3-540-36583-4_14
H. Takagi, T. Hiroi, L. Yang, Y. Tada, Y. Yuki, K. Takamura, R. Ishimitsu, H. Kawauchi, H. Kiyono, F. Takaiwa, A rice-based edible vaccine expressing multiple T cell epitopes induces oral tolerance for inhibition of Th2-mediated IgE responses Proceedings of the National Academy of Sciences of the United States of America. ,vol. 102, pp. 17525- 17530 ,(2005) , 10.1073/PNAS.0503428102
Gary Walsh, Biopharmaceutical benchmarks 2006 Nature Biotechnology. ,vol. 24, pp. 769- 776 ,(2006) , 10.1038/NBT0706-769
Henryk Lubon, Transgenic animal bioreactors in biotechnology and production of blood proteins Biotechnology annual review. ,vol. 4, pp. 1- 54 ,(1998) , 10.1016/S1387-2656(08)70066-8
Pablo Umaña, Joël Jean–Mairet, Radmila Moudry, Hanspeter Amstutz, James E. Bailey, Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity Nature Biotechnology. ,vol. 17, pp. 176- 180 ,(1999) , 10.1038/6179